Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: Results of a randomized, controlled, phase II trial

Journal of the American College of Cardiology

Volumn 44, Issue 6, 2004, Pages 1181-1186

  Torre Amione, Guillermo ^a,e   Sestier, François ^b   Radovancevic, Branislav ^c   Young, James ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c TEXAS HEART INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; IMMUNOMODULATION; INFLAMMATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RISK; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4444269967     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.06.047     Document Type: Article

References (24)

1. S. Hegewisch, H.J. Weh, D.K. Hossfeld TNF-induced cardiomyopathy Lancet 335 1990 294 295
2. F.D. Pagani, L.S. Baker, C Hsi Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs J Clin Invest 90 1992 389 398
3. M.S. Finkel, C.V. Oddis, T.D Jacob Negative inotropic effects of cytokines on the heart mediated by nitric oxide Science 257 1992 387 389
4. M.B. Fowler, J.A. Laser, G.L Hopkins Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response Circulation 74 1986 1290 1302
5. A. Blum, H. Miller Role of cytokines in heart failure Am Heart J 135 1998 181 186
6. D.L. Mann, J.J.V. McMurray, M. Packer Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL) Circulation 109 2004 1594 1602
7. E.S. Chung, M. Packer, K.H Lo Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
8. D.L. Mann, J.B. Young Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines Chest 105 1994 897 904
9. J.E. Parrillo, R.E. Cunnion, S.E Epstein A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy N Engl J Med 321 1989 1061 1068
10. L. Gullestad, H. Aass, J.G Fjeld Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure Circulation 103 2001 220 225
11. A. Staudt, F. Schaper, V Stangl Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution Circulation 103 2001 2681 2686
12. S. Babaei, D.J. Stewart, P. Picard, J.C. Monge Effects of VasoCare therapy on the initiation and progression of atherosclerosis Atherosclerosis 162 2002 45 53
13. G.M. Shivji, H. Suzuki, A.S Mandel The effect of VAS972 on allergic contact hypersensitivity J Cutan Med Surg 4 2000 132 137
14. Y. Nolan, A. Minogue, E Vereker Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's immune modulation therapy Neuroimmunomodulation 10 2002 40 46
15. 2 recovery rates in patients with advanced peripheral arterial occlusive disease Int Angiol 22 2003 141 147
16. C. McGrath, R. Robb, A.J Lucas A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication Eur J Vasc Endovasc Surg 23 2002 381 387
17. M. Packer Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure J Card Failure 7 2001 176 182
18. M. Packer, C.M. O'Connor, J.K Ghali Effect of amlodipine on morbidity and mortality in severe chronic heart failure N Engl J Med 335 1996 1107 1114
19. B. Pitt, F. Zannad, W.J Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
20. C. Torp-Pedersen, M. Moller, P.E Bloch-Thomsen Dofetilide in patients with congestive heart failure and left ventricular dysfunction N Engl J Med 341 1999 857 865
21. 2, and PAF J Clin Invest 101 1998 890 898
22. G. Torre-Amione, W. Maclellan, D Kapadia Tumor necrosis factor- is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection Transplant Proc 30 1998 875 877
23. J.D. Harding, V. Piacentino 3rd, J.P Gaughan Electrophysiological alterations after mechanical circulatory support in patients with advanced cardiac failure Circulation 104 2001 1241 1247
24. B. Vrtovec, R. Delgado, A Zewail Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure Circulation 107 2003 1764 1769